Abstract
Purpose To investigate the effectiveness of mineralocorticoid receptor (MR) antagonist in patients with steroid-induced central serous chorioretinopathy (CSC). Methods A retrospective review was conducted of steroid-induced CSC patients who were treated with the MR antagonist spironolactone 50 mg once per day for at least 1 month. The primary outcome measure was complete resolution rate of subretinal fluid (SRF) after spironolactone treatment. Secondary outcomes included central subfield thickness (CST), subfoveal choroidal thickness (SFCT), and best-corrected visual acuity (BCVA) changes after spironolactone treatment. Results Seventeen eyes from 15 patients were included in this study. Conditions warranting chronic systemic steroid use were myasthenia gravis (6/15, 40%), glomerulonephritis (5/15, 33.3%), and organ transplantation (4/15, 26.7%). Mean symptom duration of CSC was 4.00 ± 3.04 months. After spironolactone treatment, 14 eyes (82.4%) showed complete resolution of SRF (P < 0.001) without discontinuation of systemic steroid. CST and BCVA were significantly improved after spironolactone treatment. SFCT was significantly decreased after spironolactone treatment. No patients experienced electrolyte imbalance after spironolactone treatment. Conclusion MR antagonist treatment may be a therapeutic option for steroid-induced CSC patients. This treatment modality may be especially beneficial for steroid-induced CSC patients who cannot discontinue steroid medication due to systemic conditions.
Highlights
Central serous chorioretinopathy (CSC) is characterized by neurosensory retinal detachment; it is a self-limiting disease that usually has a good visual prognosis
A retrospective review was conducted of steroid-induced central serous chorioretinopathy (CSC) patients who were treated with the mineralocorticoid receptor (MR) antagonist spironolactone 50 mg once per day for at least 1 month. e primary outcome measure was complete resolution rate of subretinal fluid (SRF) after spironolactone treatment
MR antagonist treatment may be a therapeutic option for steroid-induced CSC patients. is treatment modality may be especially beneficial for steroid-induced CSC patients who cannot discontinue steroid medication due to systemic conditions
Summary
Jin Young Kim and Ju Byung Chae contributed to this work. Received 21 March 2018; Revised 14 May 2018; Accepted 3 June 2018; Published 22 July 2018. To investigate the effectiveness of mineralocorticoid receptor (MR) antagonist in patients with steroid-induced central serous chorioretinopathy (CSC). A retrospective review was conducted of steroid-induced CSC patients who were treated with the MR antagonist spironolactone 50 mg once per day for at least 1 month. E primary outcome measure was complete resolution rate of subretinal fluid (SRF) after spironolactone treatment. Secondary outcomes included central subfield thickness (CST), subfoveal choroidal thickness (SFCT), and best-corrected visual acuity (BCVA) changes after spironolactone treatment. 14 eyes (82.4%) showed complete resolution of SRF (P < 0.001) without discontinuation of systemic steroid. MR antagonist treatment may be a therapeutic option for steroid-induced CSC patients. Is treatment modality may be especially beneficial for steroid-induced CSC patients who cannot discontinue steroid medication due to systemic conditions MR antagonist treatment may be a therapeutic option for steroid-induced CSC patients. is treatment modality may be especially beneficial for steroid-induced CSC patients who cannot discontinue steroid medication due to systemic conditions
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have